CDT Equity Expands into Peptides with $10M Valuation Cap Investment in Pep'd — CDT Equity Inc.

Event summary

CDT Equity invested in Pep'd via a SAFE note with a $10M valuation cap, convertible upon Pep'd's next equity financing.
Pep'd operates a telehealth platform for peptide therapies across 50 US states, combining clinical care with in-house research.
The US peptide market is projected to grow at 8.7% CAGR from 2026 to 2033, reaching $294.6B by 2033.
CDT CEO Dr. Andrew Regan is also Pep'd's sole shareholder and director, creating a potential governance overlap.

The big picture

CDT's investment in Pep'd aligns with its strategy of backing AI-enabled biopharmaceutical platforms, reflecting broader industry trends toward data-driven drug discovery. The deal also underscores the growing convergence of telehealth and specialized therapeutics, as well as the regulatory uncertainties shaping the peptide market. With a $10M valuation cap, CDT gains exposure to a high-growth sector while leveraging its expertise in asset repositioning and strategic partnerships.

What we're watching

Governance Dynamics: How CDT's dual role in Pep'd—through its CEO's ownership—will affect decision-making and potential conflicts of interest.
Regulatory Headwinds: The pace at which US regulators establish frameworks for peptide therapeutics, which could impact Pep'd's operational model.
Execution Risk: Whether Pep'd can sustain its vertically integrated model while scaling, given the capital-intensive nature of peptide research and telehealth integration.